Match!
Gian Paolo Fadini
University of Padua
EndocrinologyProgenitor cellStem cellDiabetes mellitusMedicine
292Publications
47H-index
8,561Citations
What is this?
Publications 309
Newest
The COVID-19 pandemic has become the leading societal concern. The pandemic has shown that the public health concern is not only a medical problem, but also affects society as a whole; so, it has also become the leading scientific concern. We discuss in this treatise the importance of bringing the world’s scientists together to find effective solutions for controlling the pandemic. By applying novel research frameworks, interdisciplinary collaboration promises to manage the pandemic’s consequenc...
Source
#2Federico BoscariH-Index: 11
Last. Gian Paolo FadiniH-Index: 47
view all 5 authors...
In late February 2020, due to the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the Italian Government closed down all educational and sport activities. In March, it introduced further measures to stop the spread of coronavirus disease (COVID-19), placing the country in a state of almost complete lockdown. We report the impact of these restrictions on glucose control among people with type 1 diabetes (T1D). Data were collected on 33 individuals with T1D who were monitor...
Source
#1Angelo Avogaro (UNIPD: University of Padua)H-Index: 68
#2Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
Source
#1Serena Tedesco (UNIPD: University of Padua)H-Index: 6
#2Stefano CiciliotH-Index: 19
Last. Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
view all 10 authors...
Mobilization of hematopoietic stem/progenitor cells (HSPCs) from the bone marrow (BM) is impaired in diabetes. Excess oncostatin M (OSM) produced by M1 macrophages in the diabetic BM signals through p66Shc to induce Cxcl12 in stromal cells and retain HSPCs. BM adipocytes are another source of CXCL12 that blunts mobilization. We tested a strategy of pharmacologic macrophage reprogramming to rescue HSPC mobilization. In vitro, PPAR-gamma activation with pioglitazone switched macrophages from M1 to...
Source
#1Roberta Cappellari (UNIPD: University of Padua)H-Index: 14
#2Marianna D’Anna (UNIPD: University of Padua)H-Index: 4
Last. Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
view all 7 authors...
AIMS/HYPOTHESIS: Cardiovascular risk in diabetes is at least in part attributable to defective angiogenesis. Since diabetes negatively affects blood cells involved in angiogenesis, we herein evaluated whether diabetes impairs proangiogenic granulocytes (PAGs). METHODS: We characterised and quantified PAGs as CD49d(+) granulocytes in peripheral blood of participants with type 2 or type 1 diabetes and in non-diabetic control participants. We evaluated PAG antigenic profile and assessed in vitro fu...
Source
#1Mario Luca Morieri (UNIPD: University of Padua)H-Index: 1
#2Vera FrisonH-Index: 3
Last. Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
view all 10 authors...
CONTEXT: In randomized controlled trials (RCTs) on type 2 diabetic (T2D) patients, the GLP-1 receptor agonist (GLP-RA) dulaglutide reduced HbA1c and body weight, but generalizability of such findings to real-world T2D patients is challenging. OBJECTIVE: We evaluated effectiveness of dulaglutide in routine clinical practice, especially in subgroups of patient that are under-represented in RCTs. DESIGN: Retrospective multicenter study. SETTING: Diabetes outpatient clinics. PATIENTS AND INTERVENTIO...
Source
#1Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
Hess et al. recently hypothesized that shifts in circulating progenitor cell populations may drive cardiovascular protection by SGLT-2 inhibitors in patients with type 2 diabetes. In this Letter, Fadini challenges that interpretation and discusses previous findings from an independent randomized placebo-controlled trial indicating that cardiovascular protection by SGLT-2 inhibitors may not directly involve circulating stem/progenitor cells.
Source
#1Mauro RigatoH-Index: 11
#2Angelo Avogaro (UNIPD: University of Padua)H-Index: 68
Last. Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
view all 4 authors...
OBJECTIVE: Lipid profile represents a driver of cardiovascular risk in type 2 diabetes. The effect of chronic insulin therapy on cholesterol levels is unclear. We aim to evaluate the effect of basal insulin on lipid profile compared to other classes of anti-hyperglycaemic agents in type 2 diabetic patients. DESIGN: We performed a meta-analysis of randomized controlled trials reporting changes of lipid parameters in type 2 diabetic patients randomized to basal insulin or other classes of anti-hyp...
Source
#1Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
Last. Angelo Avogaro (UNIPD: University of Padua)H-Index: 68
view all 7 authors...
Background and aims In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM.
Source
#1Gian Paolo Fadini (UNIPD: University of Padua)H-Index: 47
#2Vera FrisonH-Index: 3
Last. Angelo Avogaro (UNIPD: University of Padua)H-Index: 68
view all 10 authors...
Aims Several GLP-1 receptor agonists (GLP-1RA) have become available for the treatment of type 2 diabetes (T2D), and evidence on their beneficial effects has evolved. We evaluated how the clinical phenotype of patients initiating GLP-1RA changed from 2010 to 2018.
2 CitationsSource
12345678910